HK inno.N to introduce biosimilars for bone disease treatment from Spain

The S.Korean company will import Prolia and Xgeva biosimilars from Spain's mAbxience

HK inno.N to introduce biosimilars for bone disease treatment from Spain
Jae-Young Han 1
2023-01-26 13:46:24 jyhan@hankyung.com
Bio & Pharma

South Korea's biohealth company HK inno.N said on Wednesday that it has signed an agreement with Spanish pharmaceutical company mAbxience SA to introduce biosimilars of bone loss treatment Prolia and Xgeva.

Under the terms of the agreement, HK inno.N plans to apply for permits by acquiring domestic licenses and copyrights for mAbxience's two biosimilars.

Denosumab, the major active ingredient of Prolia and Xgeva, is effective in preventing osteoporosis and cancer-related skeletal complications. The patent for both drugs is set to expire in 2025.

HK inno.N to introduce biosimilars for bone disease treatment from Spain

HK inno.N said that it would secure a new growth engine by quickly seeking domestic approval for the biosimilars after the patent expires.

"We will provide new treatment options to patients through the introduction of biosimilars," said Kwak Dal-won, CEO of HK inno.N.

mAbxience is a biopharmaceutical developer in Spain and is currently conducting clinical trials for denosumab biosimilars.

Write to Jae-Young Han at jyhan@hankyung.com
#HK inno.N #mAbxience #biosimilars #Prolia #Xgeva #denosumab

HK inno.N's K-CAB to get insurance benefits in China

HK inno.N's K-CAB to get insurance benefits in China

HK inno.N's K-CAB South Korea’s 30th novel medicine K-CAB Tab (active ingredient: tegoprazan), a gastroesophageal reflux disease (GERD) treatment of HK inno.N, will receive insurance coverage in China.According to industry sources on Thursday, K-CAB Tab was included in the National Reimbu

HK inno.N gets approval to sell K-CAB in Singapore

HK inno.N gets approval to sell K-CAB in Singapore

HK inno.N's K-CAB South Korean biohealth company HK inno.N said on Wednesday that it has received an item approval for K-CAB, a new drug for gastroesophageal reflux disease (GERD), from Singaporian authorities.K-CAB is the 30th domestic new drug released by HK inno.N in 2019 and is a new potass

HK inno.N receives sales permit for ulcer treatment in China

HK inno.N receives sales permit for ulcer treatment in China

HK inno.N scientist at a lab in Hanam, Gyeonggi Province HK inno.N is expediting its global expansion with its latest drug K-Cab designed to treat peptic ulcers.The South Korean pharmaceutical company announced Thursday it received the sales permit from China’s National Medical Products

HK inno.N’s K-CAB a blockbuster drug with $843 million exports

HK inno.N’s K-CAB a blockbuster drug with $843 million exports

HK inno.N's K-CAB, a gastroesophageal reflux disease (GERD) treatment drug South Korea’s HK inno.N Corp. has signed a 640 billion won ($540 million) contract to license out its technology for K-CAB, a gastroesophageal reflux disease drug, to Braintree Laboratories Inc., a subsidiary of US
(* comment hide *}